A Phase 1 Dose-Escalation and Expansion Study of BGB-16673 in Patients With B-Cell Malignancies

Status:
Recruiting

Trial end date:
2024-03-30

Target enrollment:

Participant gender:

Study consists of two parts to explore BGB-16673 recommended dosing, a part 1 monotherapy dose finding and a part 2 (cohort expansion in two cohorts)

Phase 1

BeiGene